Kura Oncology, Inc. (KURA) Upgraded at Zacks Investment Research
Kura Oncology, Inc. (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday. The firm currently has a $17.00 price objective on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 15.25% from the stock’s previous close.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
KURA has been the subject of a number of other reports. Cowen and Company began coverage on Kura Oncology in a research note on Thursday, September 7th. They issued an “outperform” rating for the company. ValuEngine downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a report on Wednesday, June 28th. Leerink Swann reissued an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Finally, Citigroup Inc. set a $13.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $16.00.
Kura Oncology (KURA) opened at 14.75 on Monday. The firm’s market cap is $408.40 million. Kura Oncology has a one year low of $4.00 and a one year high of $15.30. The stock’s 50 day moving average price is $9.73 and its 200-day moving average price is $9.24.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. Analysts forecast that Kura Oncology will post ($1.53) earnings per share for the current year.
Institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. bought a new position in Kura Oncology during the first quarter worth $533,000. Renaissance Technologies LLC increased its holdings in shares of Kura Oncology by 158.8% in the first quarter. Renaissance Technologies LLC now owns 79,200 shares of the company’s stock valued at $697,000 after purchasing an additional 48,600 shares during the last quarter. Alethea Capital Management LLC increased its holdings in shares of Kura Oncology by 128.1% in the second quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after purchasing an additional 108,577 shares during the last quarter. Nationwide Fund Advisors acquired a new position in shares of Kura Oncology in the first quarter valued at $136,000. Finally, Segantii Capital Management Ltd bought a new position in shares of Kura Oncology in the first quarter valued at about $120,000. 39.07% of the stock is owned by institutional investors and hedge funds.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.